Prescribing information

 

       

Preview or download our range of resources specifically designed for HCPs, highlighting the key benefits of REVOLADE for your ITP patients.

Summary Leaflet

SUMMARY LEAFLET

A piece about ITP treatment goals as well as REVOLADE’s platelet response, dose adjustment, mechanism of action and safety profile.

Preview

 

Summary Leaflet

2019 INTERNATIONAL CONSENSUS REPORT (ICR) LEAFLET

Providing a summary of the updated recommendations, including therapy goals, strength of supporting data for treatment, personalising treatment plans and TPO-RAs for subsequent ITP therapy.

Preview

 

Indication

REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1

REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.1

REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.1

Abbreviations: HCP, healthcare professional; HCV, hepatitis C virus; ICR, international consensus report; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia; TPO-RA, thrombopoietin-receptor agonist.

Reference

  1. REVOLADE Summary of Product Characteristics.
HCP20-C046 September 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/7819/smpc

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]